Increased circulatory levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes

被引：39

作者：

Sindhu S. ^{[1
,4
]}

Akhter N. ^{[1
]}

Arefanian H. ^{[2
]}

Al-Roub A.A. ^{[1
]}

Ali S. ^{[1
]}

Wilson A. ^{[1
]}

Al-Hubail A. ^{[3
]}

Al-Beloushi S. ^{[2
]}

Al-Zanki S. ^{[1
]}

Ahmad R. ^{[1
]}

机构：

[1] Immunology Unit, P.O. Box 1180, Dasman

[2] Islet Biology Unit, P.O. Box 1180, Dasman

[3] Clinical Laboratory, P.O. Box 1180, Dasman

[4] Animal and Zebrafish Core Facility, Dasman Diabetes Institute (DDI), P.O. Box 1180, Dasman

来源：

Journal of Diabetes & Metabolic Disorders | / 16卷 / 1期

关键词：

Chemokines; CX3CL1; Cytokines; Fractalkine; Inflammation; Obesity; Type-2; diabetes;

D O I：

10.1186/s40200-017-0297-3

中图分类号：

学科分类号：

摘要：

Background: Fractalkine (CX3CL1) is involved in the development of numerous inflammatory conditions including metabolic diseases. However, changes in the circulatory fractalkine levels in type-2 diabetes (T2D) and their relationship with inflammatory chemokines/cytokines remain unclear. The aim of the study was to determine the T2D-associated modulations in plasma fractalkine levels and investigate their relationship with circulatory chemokines/cytokines. Methods: A total of 47 plasma samples were collected from 23 T2D and 24 non-diabetic individuals selected over a wide range of body mass index (BMI). Clinical metabolic parameters were determined using standard commercial kits. Fractalkine and chemokines/cytokines were measured using Luminex X-MAP® technology. C-reactive protein (CRP) was measured by ELISA. The data were compared using unpaired t-test and the dependence between two variables was assessed by Pearson's correlation coefficient (r). Results: Plasma fractalkine levels were significantly higher (P = 0.005) in T2D patients (166 ± 14.22 pg/ml) as compared with non-diabetics (118 ± 8.90 pg/ml). In T2D patients, plasma fractalkine levels correlated positively (P ≤ 0.05) with inflammatory chemokines/cytokines including CCL3 (r = 0.52), CCL4 (r = 0.85), CCL11 (r = 0.51), CXCL1 (r = 0.67), G-CSF (r = 0.91), IFN-α2 (r = 0.97), IL-17A (r = 0.79), IL-1β (r = 0.97), IL-12P70 (r = 0.90), TNF-α (r = 0.58), and IL-6 (r = 0.60). In non-diabetic individuals, fractalkine levels correlated (P ≤ 0.05) with those of CCL4 (r = 0.49), IL-1β (r = 0.73), IL-12P70 (r = 0.41), and TNF-α (r = 0.50). Notably, plasma fractalkine levels in T2D patients associated with systemic inflammation (CRP) (r = 0.65, P = 0.02). Conclusions: The altered plasma fractalkine levels associate differentially with inflammatory chemokines/cytokines in T2D patients which may have implications for T2D immunopathogenesis. © 2017 The Author(s).

引用

共 42 条

[1]

Luca C., Olefsky J.M., Inflammation and insulin resistance, FEBS Lett, 582, pp. 97-105, (2008)

[2]

Shoelson S.E., Lee J., Goldfine A.B., Inflammation and insulin resistance, J Clin Invest, 116, pp. 1793-1801, (2006)

[3]

Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., Kwon B.S., Erickson K.L., Yu R., Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters, Int J Obes, 30, pp. 1347-1355, (2006)

[4]

Jung U.J., Choi M.S., Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease, Int J Mol Sci, 15, pp. 6184-6223, (2014)

[5]

Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F., Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study, Diabetes, 52, pp. 812-817, (2003)

[6]

Bala M., Kopp A., Wurm S., Buchler C., Scholmerich J., Schaffler A., Type 2 diabetes and lipoprotein metabolism affect LPS-induced cytokine and chemokine release in primary human monocytes, Exp Clin Endocrinol Diabetes, 119, pp. 370-376, (2011)

[7]

Hakimizadeh E., Shamsizadeh A., Nazari M., Arababadi M.K., Rezaeian M., Vazirinejad R., Jamali Z., Poor N.M., Khorramdelazad H., Darakhshan S., Hassanshahi G., Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on Iranian diabetic patients, Clin Lab, 59, pp. 531-537, (2013)

[8]

Takahashi K., Ohara M., Sasai T., Homma H., Nagasawa K., Takahashi T., Yamashina M., Ishii M., Fujiwara F., Kajiwara T., Taneichi H., Takebe N., Satoh J., Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity, Diabetes Metab Res Rev, 27, pp. 830-833, (2011)

[9]

Nunemaker C.S., Chung H.G., Verrilli G.M., Corbin K.L., Upadhye A., Sharma P.R., Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function, J Endocrinol, 222, pp. 267-276, (2014)

[10]

Vasudevan A.R., Wu H., Xydakis A.M., Jones P.H., Smith E.O., Sweeney J.F., Corry D.B., Ballantyne C.M., Eotaxin and obesity, J Clin Endocrinol Metab, 91, pp. 256-261, (2006)

← 1 2 3 4 5 →